WordNet

stated explicitly or in detail; "needed a specific amount"
a medicine that has a mitigating effect on a specific disease; "quinine is a specific for malaria"
(sometimes followed by `to'
being or affecting a disease produced by a particular microorganism or condition; used also of stains or dyes used in making microscope slides; "quinine is highly specific for malaria"; "a specific remedy"; "a specific stain is one having a specific affinity for particular structural elements"
relating to or distinguishing or constituting a taxonomic species; "specific characters"
inflammation of muscle tissue

PrepTutorEJDIC

《名詞の前にのみ用いて》『特定の』,一定の・『明確な』,明白な・(そのものに)『特有の』,独特の《+『to』+『名』》・〈C〉(…の)特効薬《+『for』+『名』》・《複数形で》明細,細部(details)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における皮膚筋炎および多発性筋炎の臨床症状 clinical manifestations of dermatomyositis and polymyositis in adults
2. 成人における皮膚筋炎および多発性筋炎の診断および鑑別診断 diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults
3. 若年性皮膚筋炎および多発性筋炎の診断 diagnosis of juvenile dermatomyositis and polymyositis
4. 炎症性ミオパチーの病因 pathogenesis of inflammatory myopathies
5. 成人における皮膚筋炎および多発性筋炎の初期治療 initial treatment of dermatomyositis and polymyositis in adults

English Journal

Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients.

Mathiesen PR, Buchvald F, Nielsen KG, Herlin T, Friis T, Nielsen S.Author information Paediatric Department, Holbaek University Hospital, Holbaek, Paediatric Pulmonary Service, DBLC, Rigshospitalet, Copenhagen, Paediatric Rheumatology Clinic, Department of Paediatrics, Aarhus University Hospital, Skejby, Department of Clinical Biochemistry and Immunology, Statens Serum Institute and Paediatric Rheumatology Unit, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.AbstractObjectives. Pulmonary disease is a rare complication in JDM, described in only a few studies. This long-term follow-up study aimed to (i) describe pulmonary involvement in a national cohort of JDM patients estimated by conventional spirometry, (ii) compare pulmonary impairment with overall JDM outcome, and (iii) identify possible associations between pulmonary impairment and myositis-specific autoantibodies (MSAs).Methods. Fifty-one JDM patients performed conventional spirometry in a cross-sectional follow-up study. The scores of the Myositis Damage Index (MDI), Myositis Damage by visual analogue scale (MYODAM-VAS) and physician's global damage assessment were used to estimate JDM outcome. ANAs, MSAs and myositis-associated autoantibodies were analysed in all patients.Results. Forty-two patients (82%) (mean follow-up time 14.3 years) had normal lung function. Four patients (8%) were diagnosed with JDM-related restrictive interstitial lung disease. No patients reported pulmonary symptoms. Patients with restrictive pulmonary function had increased long-term damage estimated by MDI (P = 0.008), MYODAM-VAS (P = 0.04), global assessment (P = 0.03) and number of organ systems involved (P = 0.009). We found significant correlation between the restrictive pulmonary function test and damage by the MDI (r = 0.43, P = 0.003), MYODAM-VAS (r = 0.44, P = 0.002), and global damage assessment (r = 0.43, P = 0.003). No association was found between the restrictive pulmonary function test and autoantibodies.Conclusion. In a long-term follow-up study of JDM patients, the majority of patients demonstrated normal lung function. However, restrictive pulmonary impairment was identified in 8% of patients, indicating a need for repetitive pulmonary follow-up in JDM patients. Restrictive pulmonary involvement was associated with increased long-term JDM damage.
Rheumatology (Oxford, England).Rheumatology (Oxford).2013 Dec 5. [Epub ahead of print]
Objectives. Pulmonary disease is a rare complication in JDM, described in only a few studies. This long-term follow-up study aimed to (i) describe pulmonary involvement in a national cohort of JDM patients estimated by conventional spirometry, (ii) compare pulmonary impairment with overall JDM outco
PMID 24310298

[Idiopathic inflammatory myopathies from the viewpoint of rheumatologists].

Gono T, Katsumata Y, Kawaguchi Y.Author information Institute of Rheumatology, Tokyo Women's Medical University.AbstractAbstract Idiopathic inflammatory myopathies (IIMs) are a group of inflammatory muscle disorders of unknown etiology; these include polymyositis (PM), dermatomyositis (DM), and inclusion body myositis. Extra-muscular manifestations such as dermatitis, arthritis, interstitial lung disease (ILD), cardiomyopathy, and enteropathy are occasional complications in patients with PM/DM. Several myositis-specific autoantibodies (MSAs) have been discovered in IIMs; these can help predict clinical characteristics, response to treatment, and prognosis. For example, anti-aminoacyl-tRNA synthetase (ARS) antibodies, including Jo-1 antibody (Ab) and anti-melanoma differentiation-associated gene 5 (MDA-5) Ab, have been associated with the manifestation of ILD in PM and DM. Anti-MDA5 Ab-associated ILD has a 1-year survival rate of 50-60%; however, short-term prognosis is relatively good in anti-ARS Ab-associated ILD. Fatal outcome occurs remarkably often within the first 6 months of anti-MDA5 Ab-associated ILD. Therefore, intensive treatment should be administered to patients harboring anti-MDA-5 Ab or showing hyperferritinemia in ILD with DM. In addition, corticosteroid occasionally induces myopathy, which is an issue arising in PM/DM treatment. Some experts recommend combination therapy of corticosteroid and an immunosuppressive agent as a first-line treatment for myositis in PM/DM. Methotrexate and azathioprine are commonly used immunosuppressive agents for myositis in western countries. Immunosuppressive agents are steroid-sparing, serving to mitigate corticosteroid-related side effects, thus making combination therapy an effective treatment option. Preventing the progression of physical dysfunction is of prime importance to patients with PM/DM. Dermatologists, neurologists, and rheumatologists should therefore work together to care for these patients before muscular and extra-muscular involvement develop progressively and irreversibly.
Brain and nerve = Shinkei kenkyū no shinpo.Brain Nerve.2013 Nov;65(11):1275-82.
Abstract Idiopathic inflammatory myopathies (IIMs) are a group of inflammatory muscle disorders of unknown etiology; these include polymyositis (PM), dermatomyositis (DM), and inclusion body myositis. Extra-muscular manifestations such as dermatitis, arthritis, interstitial lung disease (ILD), cardi
PMID 24200605

[Idiopathic inflammatory myopathies from the viewpoint of a neurologist].

Shimizu J.Author information Department of Neurology, University of Tokyo Hospital.AbstractAbstract Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of systemic autoimmune disorders characterized by inflammation of skeletal muscle. In Japan, patients with IIMs usually visit a dermatologist, rheumatologist, or neurologist depending on the main symptom. Because most of the patients with IIMs have muscle weakness as a main symptom, muscle biopsy is usually performed to differentiate these from other non-inflammatory myopathies. Thus, neurologists in Japan tend to consider mostly the pathological findings in the diagnosis and classification of IIMs. From this background, IIMs have been classified into four pathologically distinct subsets: polymyositis, dermatomyositis, necrotizing autoimmune myositis, and sporadic inclusion body myositis. However, in clinical practice, the percentage of patients with typical pathological findings is generally not high. Therefore, other clinical factors, including rash or clinical complications (malignancy, collagen diseases, or interstitial pneumonitis), have been used along with pathological classification. With the recent discovery of new myositis-specific autoantibodies (MSAs) by rheumatologists and dermatologists, it has been suggested that the presence of a MSA is another important factor for classification. To develop useful methods of classification and to reveal the pathological mechanisms of IIMs, further collaborative studies by dermatologists, rheumatologists, and neurologists are necessary.
Brain and nerve = Shinkei kenkyū no shinpo.Brain Nerve.2013 Nov;65(11):1269-74.
Abstract Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of systemic autoimmune disorders characterized by inflammation of skeletal muscle. In Japan, patients with IIMs usually visit a dermatologist, rheumatologist, or neurologist depending on the main symptom. Because most of th
PMID 24200604

Japanese Journal

膠原病の病型・予後判定に有用な新しい特異的自己抗体検査 (特集最近のトピックス2014 Clinical Dermatology 2014) -- (新しい検査法と診断法)

濱口儒人,竹原和彦
臨床皮膚科 68(5), 58-61, 2014-04
NAID 40020075147

抗TIF1抗体と抗SRP抗体が共に陽性となった皮膚筋炎の1例

簗場瑞貴,藤沼千尋,伊原千夏 [他],鈴木貴子,岩澤うつぎ,濱口儒人
日本皮膚科学会雑誌 124(5), 927-931, 2014
70歳，男性．両眼瞼が淡紅色浮腫状で，前額，内眼角，両頬，頭頸部に紫紅色斑，爪囲紅斑と爪郭部の毛細血管拡張がみられた．後頸部の生検像で表皮基底層の液状変性，真皮上層の血管周囲にリンパ球浸潤があった．CK, LDHがわずかに上昇し大腿，項部の軽度筋力低下があったが，筋電図と大腿部MRIでは筋炎所見を認めなかった．全身精査で間質性肺炎，悪性腫瘍の合併はなかった．プレドニゾロン内服にて皮疹とCK値上昇は …
NAID 130003397427